health · family: the solution exists but nobody can afford it
the drug existsbut not here
Cryptococcal meningitis kills 130,000 per year in Africa because the essential drug is unregistered across the continent
Problem statement
Cryptococcal meningitis causes approximately 194,000 cases and 147,000 deaths per year globally, representing about 19% of all AIDS-related deaths, most of them in Africa; DNDi puts the 2023 toll in Africa at 130,000 deaths (the figure in this brief's title). The WHO-recommended first-line treatment is a combination of flucytosine and liposomal amphotericin B (with fluconazole), which DNDi says can drastically reduce deaths. Flucytosine is registered in only a few African countries despite the continent bearing most of the global burden — meaning most patients do not have access to it, and treatment in practice is often fluconazole alone, which DNDi characterizes as "ineffective". The drug access gap is not a technical failure: flucytosine exists and works. It is a failure of registration and access — in DNDi's words, effective treatments are "often too expensive, unavailable, or not accessible at health facilities in areas where people are most affected."
Why this matters
With 147,000 deaths annually and fluconazole alone described by DNDi as ineffective, the treatment gap is directly and preventably lethal at scale. Global HIV funding cuts have disrupted advanced HIV disease services in Africa, the health workforce is shrinking, and flucytosine stockouts are looming. DNDi developed a sustained-release pellet formulation of flucytosine designed to replace the current every-six-hours dosing schedule with twice-daily administration, entered Phase II trials in Malawi and Tanzania (announced 15 April 2025), and explicitly designed the formulation to be administrable to comatose patients via nasogastric tube. The underlying problem — unregistered essential medicine, limited supply, HIV funding cuts — will persist regardless of whether the new formulation succeeds unless access and registration structures change.
What’s been tried and why it hasn’t worked
Flucytosine is a key component of WHO's first-line regimen, yet it is registered in only a few African countries and availability is very limited; the sources do not say why registration has not happened more widely. The current formulation (six-hourly tablets) is difficult to administer in overburdened, resource-limited settings: six-hourly dosing can lead to missed doses, and many patients arrive at hospital already in a coma, so staff crush the tablets and give them by nasogastric tube, a method not formally approved. Amphotericin B, the companion drug, is delivered intravenously and can be toxic to the kidneys, which DNDi says makes it impractical to administer in many settings. Supplies of flucytosine were already limited across many countries before the HIV funding cuts, and DNDi warns that widespread stockouts are near.
What would unlock progress
A twice-daily sustained-release formulation appropriate for nasogastric administration (DNDi's current Phase II candidate) would reduce the clinical burden of administering flucytosine to severely ill patients, potentially expanding the settings where guideline-recommended treatment is feasible. But formulation alone does not solve registration: coordinated regulatory submissions across high-burden African countries, ideally through the African Medicines Agency or national regulatory authority coalitions, would need to accompany any new product launch. A viable non-donor supply mechanism — whether through government procurement pools, tiered pricing agreements with generic manufacturers, or access-conditioned licensing — is necessary for durability.
Entry points for student teams
A policy or health systems team could map the exact regulatory status of flucytosine across the 30 highest-burden countries, identify where the submission gap is a resource problem versus a political economy problem, and model what a coordinated regional registration campaign would cost and require. A drug delivery or formulation team could engage with the Phase II trial design to understand what physical and stability specifications a sustained-release pellet formulation must meet for tropical primary care settings. A global health financing team could analyze what access-conditioned licensing structures have succeeded for other off-patent essential medicines and assess whether any are applicable here.
Genes
Structural cousins: stuck the same way, in other fields
Sources
DNDi press release, "New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease", DNDi, 15 Apr 2025, accessed 2026-02-23; DNDi disease page, "Symptoms, transmission, and current treatments for cryptococcal meningitis", DNDi, last updated September 2025, accessed 2026-02-23 go to source 1 ↗ go to source 2 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
DNDi is the organization that developed and is trialing the sustained-release flucytosine formulation. Both sources are institutional program documentation from DNDi itself, characterizing the disease burden, treatment gap, and drug access failure from the perspective of the research organization managing the intervention.
Source type: Self-articulated
Reconciliation 2026-09-30: Both sources were read in full on 2026-09-30, fetched directly from https://dndi.org/press-releases/2025/new-treatment-cryptococcal-meningitis-enters-phase-ii-trial/ (press release dated 15 April 2025) and https://dndi.org/diseases/cryptococcal-meningitis/facts/ (disease page, last updated September 2025). (1) The text said sub-Saharan Africa bears "roughly 90%" of the burden, twice. Neither source gives a percentage; the disease page says most of the deaths are in Africa, and the press release says cryptococcal meningitis claimed 130,000 lives in Africa in 2023. The text now says "most of them in Africa" and "most of the global burden", and dates the 130,000 figure to 2023. (2) The text said the WHO first-line combination "substantially improves survival over alternatives". The disease page says the disease can be treated effectively with a combination of drugs and that effective treatments exist to drastically reduce deaths; the WHO regimen it lists is liposomal amphotericin B plus flucytosine, with fluconazole. The sentence now says that. (3) The text said clinicians "across most of sub-Saharan Africa are forced to use fluconazole monotherapy" and that DNDi calls it ineffective "as a first-line agent". The disease page says most patients do not have access to flucytosine and that treatment is often just fluconazole, "which is ineffective"; it does not say "first-line agent". The sentence now follows the source; the quoted word "ineffective" is confirmed in the source. (4) The text said flucytosine is "off-patent" and called the gap "a regulatory and commercial failure". Neither source mentions patents or a commercial failure; the disease page says effective treatments are "often too expensive, unavailable, or not accessible at health facilities in areas where people are most affected". The text now says registration and access, with that quotation. (5) The text named "PEPFAR contractions" twice and "PEPFAR-era funding contractions". Neither source names PEPFAR; the press release says "global HIV funding cuts" and describes disrupted advanced HIV disease services in Africa, a shrinking health workforce and looming flucytosine stockouts. The text now says that, without the earlier "highest-burden countries" scoping, which neither source uses. (6) The text said the trial entered Phase II "in February 2025". No date appears in either source other than the press release's own date, 15 April 2025; the text now says "announced 15 April 2025". (7) The text listed "no commercial sponsor" as part of the underlying problem. Neither source says this; the press release names Mylan Laboratories (a Viatris company) as DNDi's development partner. Replaced with "limited supply". (8) The text said flucytosine "has been on WHO's Essential Medicines List", that "international advocacy has called for expanded registration for years", and that the absence of a commercial sponsor explains why regulatory submissions "have not occurred at scale". None of this is in either source. The sentence now says flucytosine is a key component of WHO's first-line regimen (press release), is registered in only a few African countries with very limited availability (disease page), and that the sources do not say why registration has not happened more widely. (9) The text said the current formulation requires "intensive nursing support". The press release says it is difficult to administer in overburdened, resource-limited settings, six-hourly dosing can lead to missed doses, and comatose patients receive crushed tablets by nasogastric tube, "a method not formally approved". The sentence now says that. (10) The text said generic manufacturers "have not entered the market at prices or volumes that would trigger national registration", that amphotericin B requires "renal monitoring" at "the edge of feasibility in many district hospitals", and that access has relied on "donated or donor-purchased supply pipelines". None of these are in either source; the disease page says amphotericin B is delivered intravenously, can be toxic to the kidneys, and is impractical in many settings, and the press release says supplies were already limited across many countries and widespread stockouts are near. The paragraph now says that. (11) The Source line now carries both pages' titles and dates copied from the pages; links unchanged. Confirmed in the sources and left as written: 194,000 cases and 147,000 deaths per year; 19% of AIDS-related deaths; 130,000 deaths in Africa (2023); registered in only a few African countries; every-six-hours dosing replaced by twice-daily; pellet form; nasogastric administration for patients who cannot swallow; Phase II in Malawi and Tanzania; DNDi as developer and trial sponsor. Not checked against any source because they are the write-up's own proposals rather than source claims: the African Medicines Agency route, procurement pools, tiered pricing, access-conditioned licensing, and the "30 highest-burden countries" scoping in the entry points. The long title's "Because the Essential Drug Is Unregistered Across the Continent" compresses the disease page's "registered in only a few African countries" and the press release's "deaths driven by treatment gaps"; the title is left unchanged and this is noted for Beth. Genome tags untouched. A second reader opened both sources again on the same day and went over every repair; two sentences were tightened (items 2 and 5) and the rest stand as written.